KRAS G12C Inhibitor Sotorasib May Offer Long-term Clinical Benefit in Patients with Non-small Cell Lung Cancer
Two-year follow up of the CodeBreaK 100 clinical trial demonstrated prolonged tumor responses and a favorable safety profile NEW...
Search/Filter
Loading...
Recurrent Non-invasive Breast Tumors May Not Always Be Related to the Primary Lesion
Patients with recurrent lesions genetically distinct from the primary tumor may require different treatment NEW ORLEANS – More than...
Natural Killer Cells Complexed With a Bispecific Antibody May Provide New Treatment Option for Patients With Advanced Lymphoma
NEW ORLEANS – Natural killer (NK) cells derived from cord blood that were activated and complexed with a CD30/CD16A...
An AI Model Can Help Predict Adverse Events From New Drug Combinations
NEW ORLEANS – Preliminary data from an artificial intelligence model could potentially predict side effects resulting from new combination...
An AI Model May Predict Elevated Pancreatic Cancer Risk Using Electronic Health Records
NEW ORLEANS – An artificial intelligence (AI) model trained using sequential health information derived from electronic health records identified...
Investigational Therapy Pyrotinib with Chemotherapy May Improve Outcomes in Patients with Pretreated HER2-positive Breast Cancer
SAN ANTONIO – Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had...
Breast Cancer Patients with Estrogen Receptor Mutations May Benefit From Early Switch to Fulvestrant/Palbociclib
Mutations were detected via circulating tumor DNA before disease progression in patients treated with an aromatase inhibitor/palbociclib for hormone...
Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Patients With Breast Cancer
Concurrent treatment with PI3K pathway inhibitors may benefit at-risk patients SAN ANTONIO – Uterine cancers that developed in patients...
Black and White Women Who Received Neoadjuvant Therapy Were Equally Likely to Have Pathologic Complete Response
Tumor biology, not race, was a more significant factor in predicting response to clinical trial treatment SAN ANTONIO – Analysis...
Black Women are More Likely to Develop Lymphedema Following Breast Cancer Treatment than White Women
SAN ANTONIO – Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was...